Evidence by GC-MS that lysine is an arginase-catalyzed metabolite of homoarginine in vitro and in vivo in humans.


Journal

Analytical biochemistry
ISSN: 1096-0309
Titre abrégé: Anal Biochem
Pays: United States
ID NLM: 0370535

Informations de publication

Date de publication:
15 07 2019
Historique:
received: 20 03 2019
revised: 23 04 2019
accepted: 23 04 2019
pubmed: 28 4 2019
medline: 9 4 2020
entrez: 28 4 2019
Statut: ppublish

Résumé

l-Homoarginine (hArg) is biosynthesized from l-arginine (Arg) and l-lysine (Lys) by arginine:glycine amidinotransferase (AGAT). AGAT also catalyzes the formation of guanidinoacetate (GAA) from Arg and glycine (Gly). GAA is converted to creatine (N-methyl guanidinoacetate) by guanidinoacetate N-methyl-transferase (GAMT). Low circulating and excretory concentrations of hArg are associated with worse cardiovascular outcome and mortality. hArg is a poor substrate of nitric oxide synthase (NOS) and a weak inhibitor of arginase. The metabolism of hArg in humans is little investigated. Previously, we found that orally administered hArg (125 mg/day) increased the plasma concentration of hArg, but not of Arg, the substrate of NOS, in healthy subjects. We newly analyzed the plasma samples collected in that study for Lys and other amino acids. Repeated measures ANOVA revealed statistically significant differences between the groups (P = 0.008) with respect to plasma Lys concentration which increased by about 8% after a 4-week hArg supplementation. In vitro, recombinant human arginase and bovine liver arginase I were demonstrated by a specific and sensitive stable-isotope GC-MS assay to hydrolyze hArg to Lys. Our results suggest that Lys is a metabolite of hArg produced by the hydrolytic activity of arginase. Arginase may play a key role in hArg homeostasis in humans.

Identifiants

pubmed: 31028716
pii: S0003-2697(19)30280-5
doi: 10.1016/j.ab.2019.04.019
pii:
doi:

Substances chimiques

Homoarginine 156-86-5
Nitric Oxide 31C4KY9ESH
Arginine 94ZLA3W45F
ARG1 protein, human EC 3.5.3.1
Arginase EC 3.5.3.1
Lysine K3Z4F929H6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

59-66

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Alexander Bollenbach (A)

Institute of Toxicology, Core Unit Proteomics, Hannover Medical School, Hannover, Germany.

Kathrin Cordts (K)

Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Germany.

Erik Hanff (E)

Institute of Toxicology, Core Unit Proteomics, Hannover Medical School, Hannover, Germany.

Dorothee Atzler (D)

Walther-Straub-Institute of Pharmacology and Toxicology, LMU Munich, Munich, Germany; Institute for Cardiovascular Prevention, LMU Munich, German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.

Chi-Un Choe (CU)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Edzard Schwedhelm (E)

Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Germany.

Dimitrios Tsikas (D)

Institute of Toxicology, Core Unit Proteomics, Hannover Medical School, Hannover, Germany. Electronic address: tsikas.dimitros@mh-hannover.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH